News & Info


Page 3 of 2912345...1020...Last »

October 13, 2016

RADIANCE Study for Treatment of Myopic Degeneration

Posted in: Research and Developments

RADIANCE is a Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study comparing the efficacy and safety of Lucentis (0.5 mg) versus verteporfin photodynamic therapy (vPDT) in 277 patients with visual impairment due to myopic choroidal neovascularization (mCNV). Patients were randomized into three treatment groups: 106 patients in group I received treatment with Lucentis on study
read more »

September 12, 2016

Webinar on Making Eye Health a Population Health Imperative: Vision for Tomorrow

Posted in: Latest News

An important report on making eye health a population health imperative is scheduled to be released to the public on Thursday, September 15. Following its release, a webinar is scheduled for Tuesday, September 20, from 2:00 until 3:15 Central Time to share highlights of the report. This is part of a consensus study by the Health and
read more »

September 10, 2016

Combined Therapies May Help Restore Vision Loss From Glaucoma

Posted in: Latest News, Research and Developments

Past studies have shown that high-contrast visual stimulation can help damaged retinal neurons regrow optic nerve fibers. By combining that knowledge with new research showing that increased activity of a protein called mTOR promotes optic nerve regeneration, scientists are hoping for a way to restore sight lost to glaucoma and other optic neuropathies. So far,
read more »

August 10, 2016

Is Blindness The “Worst Ailment”?

Posted in: Daily Living, Latest News, Low Vision Rehabilitation, Research and Developments

by Dan Roberts A recent online nationwide poll (1) has joined similar past studies in revealing that people consider vision loss to be the “worst ailment that could happen to them relative to losing memory, speech, hearing, or a limb.” The researchers’ intent was to “underscore the importance of focusing on preservation of eye health and the
read more »

July 27, 2016

Finally, A Promising Breakthrough For Dry AMD

Posted in: Latest News, Research and Developments

Genentech, Inc., a leading pharmaceutical developer, is currently conducting two phase III trials studying the drug lampalizumab as a potential treatment for advanced dry macular degeneration, also known as geographic atrophy (GA). Patients who have been diagnosed with GA are encouraged to participate in the trials, which are being conducted at hundreds of locations in
read more »

July 23, 2016

Lions Center for the Blind Needs Support

Posted in: Latest News

The Lions Center for the Blind (LCB), a nonprofit organization with offices in Oakland and Fairfield, CA, has announced that it will cease operations effective August 31, 2016, unless significant additional funding is received prior to that date. The 74-year-old service organization will have to close its doors due to a lack of funding unless new sources
read more »

July 19, 2016

Anti-depressant Drugs May Someday Help Prevent Macular Degeneration

Posted in: Latest News, Research and Developments

Tests in a mouse model of macular degeneration have shown that anti-depressant drugs already on the market prevent damage to the light cells in the retina. In a study published in Proceedings of the National Academy of Sciences, a University of Wisconsin—Madison research team pinpoints how immune abnormalities beneath the retina result in macular degeneration.
read more »

June 9, 2016

For Some, Switching ANTI-VEGF Treatments Midstream Could Be Harmful

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Switching from Lucentis to Eylea could result in worsening of the retinal condition of some people with wet (exudative) AMD. Since the advent of anti-VEGF drug treatments for wet AMD, research has verified that blood vessel growth and leakage (neovascularization) usually diminishes in patients who are switched from either Lucentis or Avastin to Eylea. A small
read more »

May 28, 2016

Summary of Research and Development — 2016

Posted in: Research and Developments

ILVSG Presentation June 2016 Dan Roberts I. INTRODUCTION This is my 11th annual summary of leading research and developments that have occurred during the past 12 months in the field of blindness and low vision. I’ll take the liberty in several cases of quoting the sources, but for the sake of conversational flow, I’ll break
read more »

May 27, 2016

Invitation to participate in paid phone survey

Posted in: Latest News

Cello Health Insight, a Healthcare Market Research Agency, is looking for people with a diagnosis of dry age-related macular degeneration with visual symptoms to participate in a marketing research study. Researchers want to learn about patients’ experiences living with age-related macular degeneration. The study consists of a telephone interview and potentially an in-person interview. This study will
read more »

May 20, 2016

Visual Impairment and Blindness in U.S. May Double by 2050

Posted in: Latest News, Research and Developments

The findings of a recent study suggest that there is a need for increased screening and interventions to identify and address treatable causes of vision loss. With the youngest of the baby boomers hitting 65 by 2029, the number of people with visual impairment or blindness in the United States is expected to double to
read more »

May 5, 2016

OPT-302 Enters Phase 2A Trials for Wet AMD

Posted in: Latest News, Research and Developments

Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, has randomized and dosed the first patient in the Phase 2A dose expansion clinical trial of OPT-302 for wet AMD. OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule, that blocks the activity of two
read more »

May 3, 2016

AMD Since Anti-VEGF

Posted in: Latest News, Therapies, Treatments, and Procedures

A National Eye Institute (NEI) study* confirms that anti-VEGF treatments have greatly improved the prognosis for patients with the wet form of age-related macular degeneration (wAMD) during the past decade. In the study of nearly 650 people, half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with
read more »

April 18, 2016

Eye Drops for Wet AMD Enter Phase 3 Trials

Posted in: Latest News

Ohr Pharmaceutical has announced that the first patient has been enrolled in a Phase III clinical trial of the company’s lead drug candidate “Squalamine”, also known as OHR-102, for the treatment of neovascular age-related macular degeneration (wet AMD). “The Phase III clinical program will examine the potential of Squalamine, when administered as part of a combination therapy,
read more »

April 14, 2016

Smoking and AMD—Are E-Cigarettes the Answer?

Posted in: Health and Nutrition, Latest News, Research and Developments

by Dan Roberts You’ve heard it before: “Tobacco Smoking Is A Major Cause Of Age Related Macular Degeneration”. According to most research, individuals 65 years of age and over double their risk of developing age-related macular degeneration (AMD) if they smoke. Why? Because tobacco smoking: Reduces levels of plasma antioxidant, a substance in the blood
read more »

Page 3 of 2912345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann